SEC Form 4 · accession 0001470831-26-000661
C4 Therapeutics, Inc. · CCCC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Laura Bessen
Director
Period of report
Jun 24, 2026
Accepted (ET)
Jun 26, 2026 · 4:28 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001662579
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $4.25 | Jun 24, 2026 | A | 62,000 | A | — | Jun 23, 2036 | Common Stock | 62,000 | 62,000 | D |
Explanation of responses
- F1This option shall vest and become exercisable in full upon the earlier to occur of (i) June 24, 2027 and (ii) the next annual meeting of the Issuer's stockholders, subject to the recipient's continued service as a member of the Board on such date.